245 related articles for article (PubMed ID: 25368284)
1. Impact of PSA levels on second-round screening for the development of prostate cancer in men with low baseline PSA levels (≤2.0 mg/ml).
Kitagawa Y; Sawada K; Urata S; Izumi K; Ueno S; Kadono Y; Konaka H; Mizokami A; Namiki M
Anticancer Res; 2014 Nov; 34(11):6739-46. PubMed ID: 25368284
[TBL] [Abstract][Full Text] [Related]
2. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
[TBL] [Abstract][Full Text] [Related]
3. Cumulative risk of developing prostate cancer in men with low (≤ 2.0 ng/mL) prostate-specific antigen levels: a population-based screening cohort study in Japan.
Sawada K; Kitagawa Y; Ito K; Takeda Y; Mizokami A; Namiki M
Int J Urol; 2014 Jun; 21(6):560-5. PubMed ID: 24372775
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
5. Simple Risk Stratification to Detect Prostate Cancer with High Gleason Score in Repeat Biopsies in a Population Screening Follow-up Study.
Kitagawa Y; Urata S; Mizokami A; Nakashima K; Koshida K; Nakashima T; Miyazaki K; Namiki M
Anticancer Res; 2015 Sep; 35(9):5031-6. PubMed ID: 26254404
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
Roobol MJ; Kranse R; de Koning HJ; Schröder FH
Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
[TBL] [Abstract][Full Text] [Related]
7. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
8. Cumulative probability of PSA increase above 4.0 NG/ML in population-based screening for prostate cancer.
Ito K; Yamamoto T; Ohi M; Takechi H; Kurokawa K; Suzuki K; Yamanaka H
Int J Cancer; 2004 Apr; 109(3):455-60. PubMed ID: 14961587
[TBL] [Abstract][Full Text] [Related]
9. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen kinetics in screen-detected prostate cancer in Japan.
Takechi H; Ito K; Yamamoto T; Miyakubo M; Ohi M; Suzuki K
Urology; 2008 Nov; 72(5):1111-5. PubMed ID: 18342926
[TBL] [Abstract][Full Text] [Related]
11. Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less.
Ito K; Yamamoto T; Ohi M; Takechi H; Kurokawa K; Suzuki K; Yamanaka H
Prostate; 2003 Sep; 57(1):8-13. PubMed ID: 12886518
[TBL] [Abstract][Full Text] [Related]
12. Does PSA velocity predict prostate cancer in pre-screened populations?
Schröder FH; Roobol MJ; van der Kwast TH; Kranse R; Bangma CH
Eur Urol; 2006 Mar; 49(3):460-5; discussion 465. PubMed ID: 16442212
[TBL] [Abstract][Full Text] [Related]
13. Changes in baseline PSA levels in Japanese men from 1988 to 2003.
Ohi M; Ito K; Yamamoto T; Miyakubo M; Takechi H; Kubota Y; Suzuki K
Urology; 2008 Jul; 72(1):95-8. PubMed ID: 18455775
[TBL] [Abstract][Full Text] [Related]
14. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ
J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
[TBL] [Abstract][Full Text] [Related]
15. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
[TBL] [Abstract][Full Text] [Related]
16. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Roobol MJ; Roobol DW; Schröder FH
Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
[TBL] [Abstract][Full Text] [Related]
17. Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer.
Berger AP; Deibl M; Strasak A; Bektic J; Pelzer AE; Klocker H; Steiner H; Fritsche G; Bartsch G; Horninger W
Urology; 2007 Jan; 69(1):134-8. PubMed ID: 17270635
[TBL] [Abstract][Full Text] [Related]
18. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE
J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831
[TBL] [Abstract][Full Text] [Related]
19. Baseline PSA in a Spanish male population aged 40-49 years anticipates detection of prostate cancer.
Angulo JC; Viñas MA; Gimbernat H; Fata FR; Granados R; Luján M
Actas Urol Esp; 2015 Dec; 39(10):605-11. PubMed ID: 26099906
[TBL] [Abstract][Full Text] [Related]
20. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
Schröder FH; Bangma CH; Roobol MJ
Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
